Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor vs Aspirin for Walking Time in PAD After Revascularization
NCT02227368Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ticagrelor in peripheral artery disease (PAD), sponsored by AstraZeneca. Started Oct 2014; status: terminated.
02
Drugs
ticagrelor
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT02227368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227368.